DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
68.94
+1.38 (2.04%)
At close: Dec 11, 2025, 4:00 PM EST
69.57
+0.63 (0.91%)
After-hours: Dec 11, 2025, 6:05 PM EST
DexCom Revenue
DexCom had revenue of $1.21B in the quarter ending September 30, 2025, with 21.64% growth. This brings the company's revenue in the last twelve months to $4.52B, up 14.21% year-over-year. In the year 2024, DexCom had annual revenue of $4.03B with 11.34% growth.
Revenue (ttm)
$4.52B
Revenue Growth
+14.21%
P/S Ratio
5.85
Revenue / Employee
$438,437
Employees
10,300
Market Cap
26.89B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
| Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
| Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
| Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
| Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
| Dec 31, 2019 | 1.48B | 444.40M | 43.08% |
| Dec 31, 2018 | 1.03B | 313.10M | 43.58% |
| Dec 31, 2017 | 718.50M | 145.20M | 25.33% |
| Dec 31, 2016 | 573.30M | 171.30M | 42.61% |
| Dec 31, 2015 | 402.00M | 142.80M | 55.09% |
| Dec 31, 2014 | 259.20M | 99.20M | 62.00% |
| Dec 31, 2013 | 160.00M | 60.10M | 60.16% |
| Dec 31, 2012 | 99.90M | 23.60M | 30.93% |
| Dec 31, 2011 | 76.30M | 27.70M | 57.00% |
| Dec 31, 2010 | 48.60M | 18.91M | 63.67% |
| Dec 31, 2009 | 29.69M | 19.86M | 201.82% |
| Dec 31, 2008 | 9.84M | 5.21M | 112.62% |
| Dec 31, 2007 | 4.63M | 2.46M | 113.23% |
| Dec 31, 2006 | 2.17M | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DXCM News
- 9 hours ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 26, 2025 in DexCom, Inc. Lawsuit - DXCM - PRNewsWire
- 14 hours ago - High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth - Seeking Alpha
- 6 days ago - HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PRNewsWire
- 7 days ago - Bragar Eagel & Squire, P.C. Urges DexCom and Wildermuth Investors to Contact the Firm Regarding Their Rights Before Upcoming Deadlines - GlobeNewsWire
- 7 days ago - Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy - Business Wire
- 15 days ago - Virtus Silvant Mid-Cap Growth Fund Q3 2025 Performance Review - Seeking Alpha
- 15 days ago - Touchstone Sands Capital Select Growth Fund Q3 Contributors And Detractors - Seeking Alpha
- 15 days ago - Bragar Eagel & Squire, P.C. Urges DexCom and Wildermuth Investors to Contact the Firm Regarding Their Rights - GlobeNewsWire